Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Combination therapy with angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinuria; however, its safety and effect on the progression of kidney disease are uncertain. Methods We provided losartan (at a dose of 100 mg per day) to patients with type 2 diabetes, a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 300, and an estimated glomerular filtration rate (GFR) of 30.0 to 89.9 ml per minute per 1.73 m(2) of body-surface area and then randomly assigned them to receive lisinopril (at a dose of 10 to 40 mg per day) or placebo. The primary end point was the first occurrence of a change in the estimated GFR (a decline of ≥ 30 ml per minute per 1.73 m(2) if the initial estimated GFR was ≥ 60 ml per minute per 1.73 m(2) or a decline of ≥ 50% if the initial estimated GFR was <60 ml per minute per 1.73 m(2)), end-stage renal disease (ESRD), or death. The secondary renal end point was the first occurrence of a decline in the estimated GFR or ESRD. Safety outcomes included mortality, hyperkalemia, and acute kidney injury. Results The study was stopped early owing to safety concerns. Among 1448 randomly assigned patients with a median follow-up of 2.2 years, there were 152 primary end-point events in the monotherapy group and 132 in the combination-therapy group (hazard ratio with combination therapy, 0.88; 95% confidence interval [CI], 0.70 to 1.12; P=0.30). A trend toward a benefit from combination therapy with respect to the secondary end point (hazard ratio, 0.78; 95% CI, 0.58 to 1.05; P=0.10) decreased with time (P=0.02 for nonproportionality). There was no benefit with respect to mortality (hazard ratio for death, 1.04; 95% CI, 0.73 to 1.49; P=0.75) or cardiovascular events. Combination therapy increased the risk of hyperkalemia (6.3 events per 100 person-years, vs. 2.6 events per 100 person-years with monotherapy; P<0.001) and acute kidney injury (12.2 vs. 6.7 events per 100 person-years, P<0.001). Conclusions Combination therapy with an ACE inhibitor and an ARB was associated with an increased risk of adverse events among patients with diabetic nephropathy. (Funded by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; VA NEPHRON-D ClinicalTrials.gov number, NCT00555217.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given that diastolic heart disease develops early in T2D and the renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of HF, the use of an ACE inhibitor or ARBs could be considered early in the treatment of hypertension, before the diagnosis of HF.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [260]
In the citing paper
“Given that diastolic heart disease develops early in T2D and the renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of HF, the use of an ACE inhibitor or ARBs could be considered early in the treatment of hypertension, before the diagnosis of HF.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [260]
In the citing paper
“Two clinical trials studied the combinations of ACE inhibitors and ARBs and found no benefits on CVD or CKD, and the medication combination had higher adverse event rates (hyperkalemia and/or AKI) (87,88).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [88]
In the citing paper
“Long-term outcome trials in patients with diabetes and CKD demonstrated no kidney or cardiovascular bene fi t of RAS blockade with combined therapy to block the RAS versus the single use of RAS inhibitors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [85]
In the citing paper
“However, combination therapy was associated with a higher rate of hyperkalemia and AKI, 85,86”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [85]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Clinical Physiology of Acid-Base and Electrolyte Disorders
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-2-176_8 · Cited by 1,156
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10363-x · Cited by 910
Research works printed but not linked: 2
- National Kidney Foundation, 2002, Am J Kidney Dis, 30, S1
- International Conference on Harmonisation, 1995, Fed Regist, 60, 11284
Cited by
Items 801–900 of 1,001
Yao, X., Wan, R., Li, C., Li, G., Zhang, B., Deng, Z., & Li, H. (2024) · Journal of Food Science · doi:10.1111/1750-3841.17258 · Cited by 4
Chrysohoou, C. A., Marketou, M. E., Aktsiali, M., & Griveas, I. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15153 · Cited by 5
Preventing the progression of chronic kidney disease: two case reports and review of the literature
Toor, M. R., Singla, A., Kim, J., Sumin, X., DeVita, M. V., & Michelis, M. F. (2014) · International Urology and Nephrology · doi:10.1007/s11255-014-0762-6 · Cited by 4
Serum Potassium in Dual Renin-Angiotensin-Aldosterone System Blockade
Seliger, S. L., & Fried, L. F. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12411213 · Cited by 4
Self-citationHabib, G. B., & Basra, S. S. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414529620 · Cited by 4
Xia, Y., Jiang, H., Chen, J., Xu, F., Zhang, G., & Zhang, D. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121540 · Cited by 4
The changing landscape of drug clinical trials on cardiometabolic diseases in China, 2009–2021
Li, C., Hao, J., Zheng, Y., Wang, C., Yang, J., Wang, W., Zhang, K., Shao, C., Wen, H., Wang, J., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01043-8 · Cited by 4
Nano Architect-Based Targeted Delivery Systems for Diabetic Nephropathy: A Review
Rawat, A., Jhawat, V., & Dutt, R. (2023) · Current Drug Targets · doi:10.2174/1389450124666230601163338 · Cited by 4
Gohda, T., Hagiwara, S., Abe, K., HIROSE, H., Shimozawa, K., Kishida, C., Sakuma, H., Adachi, E., Koshida, T., Suzuki, Y., et al. (2024) · Juntendō Igaku/Juntendo igaku · doi:10.14789/ejmj.jmj24-0031-p · Cited by 4
Patel, P., Ammon, J. P., Battle, S. J., & DiPette, D. J. (2025) · Southern Medical Journal · doi:10.14423/smj.0000000000001775 · Cited by 4
Hypertension Treatment for Patients with Advanced Chronic Kidney Disease
Sinha, A. D., & Agarwal, R. (2014) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-014-0400-y · Cited by 5
Renin Angiotensin Aldosterone System Blockers
Shibata, S., & Fujita, T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00024-x · Cited by 7
Diabetes and the Kidney: Sweet Dreams
Novak, J. E., & Yee, J. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2018.01.001 · Cited by 4
Chronische Nierenerkrankung – eine kardiovaskuläre Höchstrisikokonstellation
Speer, T., Schunk, S. J., & Fliser, D. (2019) · Der Internist · doi:10.1007/s00108-019-00686-y · Cited by 6
Tailoring treatment of hyperkalemia
Coutrot, M., Dépret, F., & Legrand, M. M. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz220 · Cited by 5
Slowing Progression of Chronic Kidney Disease
Drawz, P. E., Hostetter, T. H., & Rosenberg, M. E. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00049-4 · Cited by 6
The effect of compound DM509 on kidney fibrosis in the conditions of the experimental model
Stavniichuk, A., Savchuk, О., Khan, A. H., Jankiewicz, W. K., Imig, J. D., & Merk, D. (2020) · Bulletin of Taras Shevchenko National University of Kyiv Series “Psychology” · doi:10.17721/1728_2748.2020.80.10-15 · Cited by 4
Ma, C.-E., Yu, P., Wei, W., & Chen, X. (2021) · Medicine · doi:10.1097/md.0000000000025991 · Cited by 4
How Can We Halt-CKD in Primary Care?: Clinical Care Paths to Manage Chronic Kidney Disease
(2021) · The Singapore Family Physician · doi:10.33591/sfp.47.8.u3 · Cited by 5
Gambaro, A., Lombardi, G., Ribichini, F. L., Mantovani, A., Bignamini, A. A., & Gambaro, G. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000003066 · Cited by 4
Alexandrou, M. E., Theodorakopoulou, M. P., Kanbay, M., & Sarafidis, P. A. (2022) · Journal of Human Hypertension · doi:10.1038/s41371-021-00641-1 · Cited by 6
Uwaezuoke, S. N., & Ayuk, A. C. (2020) · EMJ Nephrology · doi:10.33590/emjnephrol/20-00077 · Cited by 4
Hyperkalaemia in Cardiological Patients: New Solutions for an Old Problem
Abrignani, M. G., Gronda, E., Marini, M., Gori, M., Iacoviello, M., Temporelli, P. L., Benvenuto, M., Binaghi, G., Cesaro, A., Maloberti, A., et al. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07551-7 · Cited by 5
Slowing Progression of Chronic Kidney Disease
Pollack-Zollman, M., & Vassalotti, J. A. (2019) · Oxford University Press eBooks · doi:10.1093/med/9780190611620.003.0012 · Cited by 4
A Young Patient with a Family History of Hypertension
Peixoto, A. J. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02240314 · Cited by 4
Combination therapy in chronic kidney disease?
Juncos, L. I., & Caputo, J. (2015) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944715579628 · Cited by 5
Wasser, W. G., Gil, A., & Skorecki, K. L. (2015) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10214 · Cited by 5
Angelow, A., Ploner, T., Grimmsmann, T., Walker, J., & Chenot, J. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4965 · Cited by 4
Blocking innate immunity to slow the progression of chronic kidney disease
Schmaderer, C., & Heemann, U. W. (2014) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-014-1031-z · Cited by 4
Finerenone in diabetic kidney disease – So far, so good
Gilbert, R. E. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.12.012 · Cited by 4
Principles of Diabetes Care and Lifestyle Modification
Moon, M. K. (2021) · Stroke revisited · doi:10.1007/978-981-16-5123-6_8 · Cited by 3
Geng, X., Huang, W., Deng, L., Xiong, Y., Zhao, Y., Yao, H., Zhou, Z., Xu, B., Xu, F., Wang, F., et al. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202401598 · Cited by 4
Preserving renal function: gliflozins, GLP1 agonists, and antialdosterones
Cice, G. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf019 · Cited by 3
Goupil, R., Tsuyuki, R. T., Santesso, N. A., Terenzi, K. A., Habert, J., Cheng, G., Gysel, S. C., Bruneau, J., Leung, A. A. C., Campbell, N. R. C., et al. (2025) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/17151635251343907 · Cited by 3
Nakamura, M., Satoh, N., Mizuno, T., Takagi, M., Horita, S., & Nangaku, M. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1677518 · Cited by 3
2024 Thai guidelines on the treatment of hypertension
Kunanon, S., Kotruchin, P., Chattranukulchai, P., Chotruangnapa, C., Roubsanthisuk, W., Vathesatogkit, P., Kunavisarut, T., Silaruks, S., Tejavanija, S., Wataganara, T., et al. (2025) · Asian Biomedicine · doi:10.2478/abm-2025-0034 · Cited by 3
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062757 · Cited by 3
Diabetische Nephropathie: Aktuelle Diagnostik und Therapie
Werth, S. C., Lehnert, H., & Steinhoff, J. (2015) · Der Internist · doi:10.1007/s00108-014-3629-0 · Cited by 3
Diabetes-Related Microvascular Complications: What Every Nurse Practitioner Needs to Know
Egan, E. A. (2017) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2016.08.030 · Cited by 3
Non-immunosuppressive therapies for childhood IgA nephropathy
Shima, Y., Nakanishi, K., & Yoshikawa, N. (2021) · Pediatric Nephrology · doi:10.1007/s00467-021-04954-8 · Cited by 3
Hypertension management in chronic kidney disease: A guide for NPs
Liddell, T. S., Henry-Okafor, Q., & Umeukeje, E. M. (2024) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000201 · Cited by 4
Park, S. J., An, H. S., Kim, S. H., Kim, S. H., Cho, H., Kim, J. H., Cho, A., Kwak, J. H., Shin, J. I., Lee, K. H., et al. (2025) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.24.096 · Cited by 3
Putting Evidence Based JNC 8 Guideline into Primary Care Practice
Ubaidi, B. A. A. (2015) · Journal of Hypertension Open Access · doi:10.4172/2167-1095.1000193 · Cited by 3
Ideguchi, T., Tsuruda, T., Sato, Y., & Kitamura, K. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0283 · Cited by 3
Pathophysiology of Hypertension in Chronic Kidney Disease and Dialysis
Griffin, K. A., Polichnowski, A. J., & BIDANI, A. K. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6436-9_3 · Cited by 3
Matoses-Jaén, M. S., García-Claudio, N., Álvarez, J., & Argente-Navarro, P. (2020) · Revista Española de Anestesiología y Reanimación · doi:10.1016/j.redar.2019.11.010 · Cited by 3
Cheng, L., Cheng, J., Peng, W., Jiang, X., & Huang, S. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9112 · Cited by 3
Huo, Z., Ye, H., Ye, P., Xiao, G., Zhang, Z., & Kong, Y. (2021) · PeerJ · doi:10.7717/peerj.11661 · Cited by 4
Chowdhury, T. A., & Ali, O. (2021) · Clinical Medicine · doi:10.7861/clinmed.2021-0144 · Cited by 3
Балыкова, Л. А., Leontyeva, I. V., Krasnopolskaya, A. V., Sadykova, D. I., Mashkina, L. S., Chegodaeva, I. Y., Хабибрахманова, З. Р., Сластникова, Е. С., Галимова, Л. Ф., & Ushakova, S. A. (2021) · Вопросы современной педиатрии · doi:10.15690/vsp.v20i4.2281 · Cited by 6
Neue Aspekte der medikamentösen Nephroprotektion
Beimler, J. (2022) · Die Innere Medizin · doi:10.1007/s00108-022-01297-w · Cited by 3
Clinical Assessment and Management of Chronic Kidney Disease Across Its Stages
Collins, A. K., Rosenberg, M. E., & Kimmel, P. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00005-x · Cited by 3
HIPERTENSÃO E DIABETES: CONCEITOS ATUAIS NA TERAPÊUTICA
Faculdade de Medicina de São José do Rio Preto (FAMERP), S., Cosenso‐Martin, L. N., Yugar‐Toledo, J. C., Faculdade de Medicina de São José do Rio Preto (FAMERP), S., Vilela-Martin, J. F., & Faculdade de Medicina de São José do Rio Preto (FAMERP), S. (2021) · Revista Brasileira de Hipertensão · doi:10.47870/1519-7522/20212803213-18 · Cited by 6
New Strategies for Volume Control in Patients with Diabetes Mellitus, a Narrative Review
Gérard, A. O., Laurain, A., Sicard, A., Merino, D., Pathak, A., Drici, M., Favrè, G., & Esnault, V. L. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081569 · Cited by 3
A Narrative Review of Signaling Pathway and Treatment Options for Diabetic Nephropathy
Semwal, B. C., Chauhan, N. S., Jyot, V., Kumar, A., Sonia, S., & Bhupendra, S. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230727093911 · Cited by 3
Linee guida ESC 2023 per il trattamento delle malattie cardiovascolari nei pazienti diabetici
Marx, N., Federici, M., Schütt, K. S., Müller‐Wieland, D., Ajjan, R., Antunes, M. J., Christodorescu, R., Crawford, C. A., Angelantonio, E. D., Eliasson, B., et al. (2024) · Giornale Ialiano di Cardiologia · doi:10.1714/4162.41558 · Cited by 6
Rossing, P. R., & Flyvbjerg, A. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch44 · Cited by 3
Petrović, M., Dragovic, T., Petrović, S., Obrenčević, K., Rančić, N., Djurasinovic, T., Petrović, D., Ignjatović, L., Rabrenović, V., Nenezić, N., et al. (2018) · Vojnosanitetski pregled · doi:10.2298/vsp180525113p · Cited by 4
Rifkin, D. E., Kiernan, M. S., & Sarnak, M. J. (2015) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.10.005 · Cited by 3
New nonabsorbable potassium-exchange resins in hyperkalaemia
Roscioni, S. S., & Heerspink, H. J. L. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.252 · Cited by 3
The Role of Systemic Blood Pressure in the Progression of Chronic Kidney Disease
Griffin, K. A., Pothugunta, K. S., Polichnowski, A. J., & BIDANI, A. K. (2015) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-015-0450-9 · Cited by 3
Treatment of albuminuria due to diabetic nephropathy: recent trial results
Horwitz, E. J., & Schelling, J. R. (2014) · Clinical Investigation · doi:10.4155/cli.14.19 · Cited by 3
NG28: Promoting patient-centred care for adults with type 2 diabetes
Meetoo, D. D., & Alsomali, S. (2016) · Nurse Prescribing · doi:10.12968/npre.2016.14.5.236 · Cited by 3
Capítulo 8 - Hipertensão e Condições Clínicas Associadas
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160158 · Cited by 4
Dual RAAS Blockade with Aliskiren in Patients with Severely Impaired Chronic Kidney Disease
Rasche, F. M., Joel, C., Ebert, T., Frese, T., Barinka, F., Busch, V., Rasche, W., Lindner, T. H., Schneider, J. G., & Schiekofer, S. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-106440 · Cited by 3
Sourij, H., Edlinger, R., Prischl, F. C., Auinger, M., Kaser, S., Horn, S., Paulweber, B., Kautzky‐Willer, A., Säemann, M. D., Prager, R., et al. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-018-1425-x · Cited by 3
Sodium–Glucose Cotransporter 2 Inhibitors and the Kidney
DeFronzo, R. A., & Abdul‐Ghani, M. A. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0071 · Cited by 4
Perioperativer Umgang mit der Dauermedikation bei kardialen Vorerkrankungen
Ninke, T., & Kilger, E. (2021) · AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie · doi:10.1055/a-1226-4720 · Cited by 3
Management of Hypertension in Chronic Kidney Disease
Cohen, J. B., & Townsend, R. R. (2016) · Springer eBooks · doi:10.1007/978-1-4939-6436-9_10 · Cited by 3
Isidto, R., Danguilan, R. A., Naidas, O. D., Villanueva, R. T., Arakama, M.-H., & Paraiso, L. M. (2023) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s387262 · Cited by 5
Borg, R., & Persson, F. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.02 · Cited by 3
Ahmed, R., de Souza, R. J., Li, V., & Anand, S. S. (2022) · medRxiv · doi:10.1101/2022.06.28.22275821 · Cited by 4
Truth and Pitfalls of Evidence-Based Medicine
Campese, V. M. (2025) · Kidney and Dialysis · doi:10.3390/kidneydial5030038 · Cited by 3
Approach to the Patient with Non-nephrotic Proteinuria
Regunathan-Shenk, R., Nobakht, E., & Cohen, S. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00058-9 · Cited by 2
Non-albuminuric chronic kidney disease in diabetes
Borg, R., & Persson, F. (2022) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1018_22 · Cited by 2
Small, A. M., & Wiviott, S. D. (2024) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.24.06600-6 · Cited by 3
The era of combination of nephroprotective agents in CKD is there
Jadoul, M. Y., & Rossing, P. R. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae260 · Cited by 2
Alqurain, A., Alotaibi, M. A., Alazmi, B. A., Aljohani, M. A., Albalawi, B. R., Alzughaibi, D. A., Alzhrani, A. F., Ahmed, R. E., Alnoumesy, H. N., Aloufi, S. A., et al. (2026) · Cureus · doi:10.7759/cureus.103029 · Cited by 2
Clinical Assessment and Management of Chronic Kidney Disease Across its Stages
Collins, A. K., Rosenberg, M. E., & Kimmel, P. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00005-6 · Cited by 4
Metabolic Disorder-Related Hypertension
Guo, Y., Zhao, J., Wang, H., Liu, S., Huang, T., & Chang, G. (2019) · Springer eBooks · doi:10.1007/978-981-15-0591-1_15 · Cited by 3
SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease
Stanton, R. C. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.03.003 · Cited by 2
Current opportunities for prevention of chronic kidney disease progression in children
POLKANOVA, V. A., Voronina, E. N., & Печкуров, Д. В. (2022) · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · doi:10.21508/1027-4065-2022-67-2-20-27 · Cited by 2
Hypertension and Chronic Kidney Disease Including Dialysis
Dhaybi, O. A., & Bakris, G. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00035-9 · Cited by 2
Liu, H., Guo, M., Zhou, Y., Jin, M., Hao, H., Yuan, Y., Dong, H., & Jia, H. (2024) · World Journal of Urology · doi:10.1007/s00345-024-05364-9 · Cited by 2
Alfaiz, A. S. (2025) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2025.100251 · Cited by 2
Morris, D. (2014) · Independent Nurse · doi:10.12968/indn.2014.15.20 · Cited by 2
Solbu, M. D., & Jardine, A. G. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv351 · Cited by 2
Should all patients with significant proteinuria take a renin-angiotensin inhibitor?
Thomas, G., & Nally, J. V. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.82a.15038 · Cited by 2
Dealing with abnormal test results in diabetes
Morris, D., & Morris, S. (2016) · Independent Nurse · doi:10.12968/indn.2016.12.22 · Cited by 5
Proteinurie im Kindesalter: Diagnostisches und therapeutisches Vorgehen
Liebau, M. C., & Weber, L. T. (2017) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-017-0284-2 · Cited by 2
Treatment Goals in Diabetic Nephropathy
Vervoort, G. (2018) · Springer eBooks · doi:10.1007/978-3-319-93521-8_25 · Cited by 2
Hypertensive Chronic Kidney Disease
Porter, A. C., Amarah, A. R., Cedillo-Couvert, E. A., & Lash, J. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52978-5.00004-5 · Cited by 2
Clinical Trials Data Management in the Big Data Era
Perez-Arriaga, M. O., & Poddar, K. A. (2020) · Lecture notes in computer science · doi:10.1007/978-3-030-59612-5_14 · Cited by 2
Sukkarieh, H. H., Bustami, R. T., Abdu, M. N., Khokhar, A. A., Salih, A. A., & Abdalla, H. K. (2020) · Saudi Medical Journal · doi:10.15537/smj.2020.10.25428 · Cited by 2
Bakker, E., Mol, P. G. M., Nabais, J. M. V., Vetter, T., Kretzler, M., Nolan, J. J., Mayer, G. J., Sundgren, A. K., Heerspink, H. J. L., Schiel, A. E., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.662642 · Cited by 2
Özbalcı, D. (2021) · Medical Hypotheses · doi:10.1016/j.mehy.2021.110619 · Cited by 2
Sindahl, P., Ofori‐Asenso, R., Hallgreen, C. E., Kemp, K., Gardarsdóttir, H., & Bruin, M. L. D. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15080 · Cited by 2
Elliott, W. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_11 · Cited by 2
Harbord, N. B., Winchester, J. F., Charen, E., Ornillo, C., Sheth, N., Feinfeld, D. A., & Dubrow, A. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-18741-9_22 · Cited by 3
Polypharmacology in Clinical Applications: Renal Polypharmacology
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_9 · Cited by 2
Metadata
- Authors
- Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., Reilly, R. F., Seliger, S. L., Warren, S. R., Watnick, S., Peduzzi, P., & Guarino, P.
- Affiliations
- Boston University (US)
- Loyola University Medical Center (US)
- VA Connecticut Healthcare System (US)
- University of New Mexico (US)
- University of Arizona (US)
- Ascension (US)
- University of Pittsburgh (US)
- VA North Texas Health Care System (US)
- University of Maryland, Baltimore (US)
- Portland VA Medical Center (US)
- Yale University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-11-14
- Volume
- 369
- Issue
- 20
- Pages
- 1892-1903
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2162368776
- Semantic Scholar
- 7e191f2ee9fe17b31623d78bf58b03d157e94654
- Cited by
- 1,169
- References
- 19
- Citations by year
- 2026: 32 · 2025: 56 · 2024: 67 · 2023: 95 · 2022: 75 · 2021: 102 · 2020: 89 · 2019: 105 · 2018: 88 · 2017: 98 · 2016: 104 · 2015: 123 · 2014: 122 · 2013: 9
- FWCI
- 90.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- diabetic nephropathy, losartan, lisinopril, ACE inhibitors, angiotensin receptor blockers, type 2 diabetes, estimated glomerular filtration rate decline, end-stage renal disease, albuminuria, hyperkalemia, acute kidney injury, drug safety, early trial termination, cardiovascular events, mortality, proteinuria, kidney disease progression
- MeSH terms
- Adult, Angiotensin-Converting Enzyme Inhibitors, Diabetic Nephropathies, Double-Blind Method, Drug Therapy, Combination, Female, Glomerular Filtration Rate, Humans, Kidney Failure, Chronic, Male, Middle Aged, Lisinopril, Losartan, Angiotensin II Type 1 Receptor Blockers, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.